Mass General Brigham has spun out AIwithCare, a company commercializing RECTIFIER, an AI tool that automates and enhances clinical trial patient screening using EHR data.
Key Details
- 1RECTIFIER, developed at Mass General Brigham, leverages Retrieval-Augmented Generation (RAG) AI to assess patient eligibility for clinical trials via EHRs, including unstructured notes and reports.
- 2In a 2024 NEJM AI study, RECTIFIER outperformed manual screening methods for a heart failure trial at lower cost.
- 3A randomized-controlled trial involving nearly 4,500 patients showed RECTIFIER doubled the enrollment rate compared to manual screening, with no differences across demographic groups.
- 4RECTIFIER is in use for over 20 clinical and research applications including oncology, neurology, pathology, and cardiology.
- 5Mass General Brigham Innovation facilitated the spinout, aiming for broader deployment across health systems via the AIwithCare platform.
- 6RECTIFIER is also being applied to population health and referral triage, showing >94% accuracy in select use cases.
Why It Matters
Accelerating and automating patient screening for trials using AI—including extraction from imaging reports—may boost trial efficiency, reduce research staff workload, and expand equitable patient access to advanced therapies. This reflects a broader trend of integrating AI into real-world clinical informatics, directly impacting radiology and multi-disciplinary care coordination.
Source
EurekAlert
Related News
•EurekAlert
AI Multimodal Models Improve Breast Cancer Recurrence Risk Prediction
Initial results from an ECOG-ACRIN and Caris Life Sciences collaboration show AI-driven multimodal models can more accurately predict recurrence risk in early-stage breast cancer.
•EurekAlert
Survey: Public Trusts Doctors Over AI, But Embraces AI For Cancer Diagnosis
Most people trust doctors more than AI for health diagnoses, but see significant potential for AI tools in cancer detection.
•EurekAlert
UCLA Researchers Present AI, Blood Biomarker Advances at SABCS 2025
UCLA Health researchers unveil major advances in breast cancer AI pathology, liquid biopsy, and biomarker strategies at the 2025 SABCS.